Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 2:14:1198972.
doi: 10.3389/fimmu.2023.1198972. eCollection 2023.

The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

Jingyao Tu  1 , Hang Liang  2 , Chunya Li  1 , Yongbiao Huang  1 , Ziqi Wang  1 , Xinyi Chen  1 , Xianglin Yuan  1
Affiliations
Review

The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

Jingyao Tu et al. Front Immunol. .

Abstract

Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advanced cancers and can improve cancer patient survival in the long term. Currently, most patients cannot benefit from immunotherapy, and some patients may experience tumor recurrence and drug resistance even if they achieve remission overcome. Numerous studies have shown that the abnormal angiogenesis state of tumors can lead to immunosuppressive tumor microenvironment, which affects the efficacy of immunotherapy. Actually, to improve the efficacy of immunotherapy, the application of anti-angiogenesis drugs to normalize abnormal tumor vessel has been widely confirmed in basic and clinical research. This review not only discusses the risk factors, mechanisms, and effects of abnormal and normalized tumor angiogenesis state on the immune environment, but summarizes the latest progress of immunotherapy combined with anti-angiogenic therapy. We hope this review provides an applied reference for anti-angiogenesis drugs and synergistic immunotherapy therapy.

Keywords: anti-angiogenesis therapy; immunotherapy resistance; tumor immunotherapy; tumor microenvironment; vascular normalization.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Tumor pathological vascular characteristics and pathology.
Figure 2
Figure 2
Factors inducing pathological angiogenesis in tumors.
Figure 3
Figure 3
Abnormal tumor angiogenesis promotes the immunosuppressive tumor microenvironment formation.
See this image and copyright information in PMC

References

    1. Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. . Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res (2019) 38(1):268. doi: 10.1186/s13046-019-1266-0 - DOI - PMC - PubMed
    1. Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. . Anti-TGF-beta/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer (2022) 10(12):e005543. doi: 10.1136/jitc-2022-005543 - DOI - PMC - PubMed
    1. Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer (2021) 124(2):359–67. doi: 10.1038/s41416-020-01048-4 - DOI - PMC - PubMed
    1. Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, et al. . Combination of oral STING agonist MSA-2 and anti-TGF-beta/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol (2022) 15(1):142. doi: 10.1186/s13045-022-01363-8 - DOI - PMC - PubMed
    1. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol (2019) 12(1):92. doi: 10.1186/s13045-019-0779-5 - DOI - PMC - PubMed

Publication types

Substances